ChemotherapyFDA-approvedFirst-line
Xeloda
Generic name: capecitabine
How it works
Is converted into a compound that interferes with DNA replication, causing cancer cells to die.
Cancer types
Colorectal Cancer— All patients
Efficacy
In clinical trials, Xeloda improved response rates and overall survival in patients with metastatic colorectal cancer.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Capecitabine for Metastatic ER Positive Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Testing Atezolizumab and Capecitabine for Triple Negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Rectal Cancer Trial Examines New Treatment Combination | Colorectal Cancer | phase-2 | — | Source → |
| Combination Therapy Shows Promise for Advanced Breast Cancer | Breast Cancer | phase-2 | The objective response rate was 25.8%, with 17 partial responses. | Source → |
| Evaluating a Combination Treatment for Metastatic Colorectal Cancer in Elderly Patients | Colorectal Cancer | phase-2 | — | Source → |
| Study Examines Effectiveness of Capecitabine in Triple-Negative Breast Cancer | Breast Cancer | observational | Adjuvant capecitabine did not improve disease-free survival (HR = 0.96; 95% CI 0.52-1.78) or overall survival (HR = 0.70; 95% CI 0.33-1.46) in univariable analyses. | Source → |
| Genetic Testing for Breast Cancer Patients on Capecitabine May Be Cost-Effective | Breast Cancer | phase-3 | The genotyping strategy yielded 1.16 QALYs at a cost of $2,832, compared to $2,677 and 1.15 QALYs for the no-genotyping strategy. | Source → |
| New Treatment Combination for Triple-Negative Breast Cancer Being Tested | Breast Cancer | phase-3 | — | Source → |
| Testing Tetrathiomolybdate and Capecitabine for Triple Negative Breast Cancer | Breast Cancer | phase-1 | — | Source → |
| Methylcobalamin May Help Prevent Hand-Foot Syndrome in Breast Cancer Patients | Breast Cancer | phase-3 | Grade ≥2 hand-foot syndrome occurred in 14.5% of patients in the methylcobalamin group, compared to 29.1% in the placebo group. | Source → |
| Capecitabine plus Temozolomide Therapy for Pancreatic Tumors | Pancreatic Cancer | observational | The objective response rates and disease control rates were 26.7 and 66.7%, respectively. | Source → |
| Lu-DOTATATE with Capecitabine Tested in Advanced Gastroenteropancreatic Neuroendocrine Tumors | Pancreatic Cancer | phase-2 | The objective response rate was 33.3% in the experimental arm versus 30.6% in the control arm. | Source → |
| Predicting Capecitabine-Induced Diarrhea in Cancer Patients | Colorectal Cancer | lab-study | The area under curve of the model was 0.907, with a specificity of 100.0% and a sensitivity of 71.4% for predicting diarrhea in colorectal cancer patients. | Source → |
| New Treatment Options for Advanced HER2-Positive Breast Cancer | Breast Cancer | phase-3 | Median overall survival for patients in the tucatinib arm was 21.9 months compared with 17.4 months for patients in the control arm. | Source → |
| Long-Term Outcomes of Pancreatic Cancer Treatment | Pancreatic Cancer | phase-3 | The median overall survival was 31.6 months in patients given GemCap. | Source → |
| Phenytoin Interaction with Capecitabine in Cancer Treatment | Colorectal Cancer | observational | — | Source → |
| Tailoring Cancer Treatment for Triple-Negative Breast Cancer Patients | Breast Cancer | phase-3 | Among immune-hot patients, the 5-year disease-free survival rate was 96.9% in the capecitabine group and 79.4% in the control group. | Source → |
| Neoadjuvant Chemotherapy for Rare Lung Tumors Shows Promise | Lung Cancer | observational | There was a 21% regression in the primary tumor size. | Source → |
| Combining two treatments for hormone receptor positive breast cancer | Breast Cancer | phase-2 | The estimated median progression-free survival for the combination was 17.7 months versus 14.6 months for letrozole alone. | Source → |
| Targeted Cancer Treatment Using Carbohydrate-Based Nanoparticles | Colorectal Cancer | lab-study | — | Source → |
| Rare Case of Ependymoma Shows Long-Term Remission with Combination Chemotherapy | Lung Cancer | observational | The patient remained in remission for approximately 29 months. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.